title: [Ototoxicity of cis-diammine glycolato platinum, 254-S].
abstract: Ototoxicity of cis-diammine glycolato platinum, 254-S, was evaluated from the results obtained in phase II studies for head & neck cancer, lung cancer, breast cancer, gastrointestinal cancer, urogenital cancer and gynecological cancer at 114 institutions, and in randomized comparative study of 254-S plus vindesine vs. cisplatin plus vindesine for advanced non-small cell lung cancer conducted at 41 institutions. In these studies, 254-S was administered at doses ranging from 80 to 100 mg/m2, repeated at least 2 times at 4-week intervals. Impaired hearing was examined in a hearing audiometry test before and after 254-S administration. The incidence of impaired hearing was 25.8% (16/62) in the 254-S phase II studies. The incidences in the randomized comparative study were 17.6% (3/17) for the 254-S/vindesine group and 20.0% (3/15) for the cisplatin/vindesine group. From these results, the ototoxicity of 254-S was thought to be similar to that of cisplatin in incidence and type.
authors.affiliation: Department of Otolaryngology, School of Medicine, Tokai University, Isehara, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Horiuchi
authors.forename: H
authors.initials: H
authors.lastname: Miyake
authors.forename: K
authors.initials: K
authors.lastname: Ota
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001299:Audiometry; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy / Q000503:physiopathology; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D006309:Hearing / Q000187:drug effects*; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000503:physiopathology; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000503:physiopathology
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C053989:nedaplatin; D002945:Cisplatin